Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:
Axitinib	
INITIATION Re-assessment required after 4 months Prerequisites (tick boxes where appropriate)	
The patient has metastatic renal cell carcinoma  and The disease is of predominant clear cell histology and The patient has documented disease progression following on and The patient has ECOG performance status of 0-2	ne previous line of treatment
CONTINUATION Re-assessment required after 4 months Prerequisites (tick box where appropriate)  O No evidence of disease progression.	

C:	D-1	
Signed.	Date:	
Oigilica.	 Daic.	